Bitcoin Info News Logo
Bitcoin NewsAlt Coin NewsMiningBlockchain EventMillionaireCrypto NewsNews
Bitcoin NewsAlt Coin NewsMiningBlockchain EventMillionaireCrypto NewsNews
Sponsorship
Sponsorship
Home/Crypto News/US Pharma Firms License Chinese Drugs Worth $18 Billion
Crypto News

US Pharma Firms License Chinese Drugs Worth $18 Billion

News
Toby Morgan
Bitcoin Info News Logo

Bitcoin Info News is an independent digital publication focused on Bitcoin, crypto markets, blockchain infrastructure, regulation, and adoption.

Follow on Google

Contact the editorial teamView newsroom and editorial contacts

Social

FacebookYouTubeTelegramXLinkedIn
Toby Morgan
Published:Jun 16, 2025
1 MIN READ
MakeBitcoin Info Newspreferred onGoogle

US pharma firms license $18B in Chinese drugs, enhancing innovation pipelines amid regulatory caution.

In This Article

  1. US Firms License One-Third of New Drugs from China
  2. Geopolitical Risks Loom Over Pharma Licensing Shift
  3. 15-Fold Increase in US-China Drug Deals Since 2020
What to Know:
  • US and Western companies license $18 billion in drugs from China.
  • US firms count on Chinese biopharma innovation.
  • Regulatory concerns arise amid economic ties.

Major US pharmaceutical companies are investing $18 billion in licensing drugs from Chinese biopharma firms as of 2024.

This trend underscores a shift towards Chinese-origin drugs, impacting US innovation and regulatory landscapes.

US Firms License One-Third of New Drugs from China

The licensing of Chinese drugs by US pharma firms has surged, with one-third of new drugs originating from China. This trend is driven by cost-effective R&D and innovative therapies.

Chinese innovators like Akeso have attracted US interest by delivering noteworthy clinical trial results. These actions reflect a strategic partnership formed amid growing US reliance on Chinese pharma.

Geopolitical Risks Loom Over Pharma Licensing Shift

Immediate effects include increased focus on Chinese innovation and regulatory scrutiny. Western pharma companies aim to diversify, but geopolitical risks could alter this trend.

The financial landscape shifts as US companies potentially curb R&D costs, though there are concerns over competitive impact on US-developed drugs and future fundraising capabilities. As Groenewegen-Lau, an industry analyst, stated:

“Beijing is not willing to significantly increase healthcare expenditure and its pharma firms need investments so it is encouraging foreign investment to come in so its innovative drugs sector can continue to grow.”

15-Fold Increase in US-China Drug Deals Since 2020

Historically, drug licensing favored Western labs. The current shift, marked by a 15-fold increase since 2020, is significant yet challenges remain similar to past geopolitical tensions.

Analyzing industry trends suggests sustained licensing activity, but regulatory and economic disputes could impact future arrangements between US and Chinese firms.

Disclaimer: The information on this website is for informational purposes only and does not constitute financial or investment advice. Cryptocurrency markets are volatile, and investing involves risk. Always do your own research and consult a financial advisor.

Article Topics

Crypto News

Editor Picks

If You Only Read 3 Things Today

Fastest way to catch the signal before you keep scrolling.

#1 Why Is Solana SOL Price Up...#2 No KYC Crypto Exchange How Bitania...#3 Strategy Adds 485 BTC Bitcoin US...

Most Read

1

Why Is Solana (SOL) Price Up Today?

Nov 18, 2026•5 MIN READ
2

No KYC Crypto Exchange: How Bitania Makes Crypto Trading Simple and Private

Nov 17, 2026•4 MIN READ
3

Strategy Adds 485 BTC: Bitcoin US Session Roundup

Nov 17, 2026•11 MIN READ
4

Why Is Hedera (HBAR) Price Down Today?

Nov 17, 2026•5 MIN READ
5

IBIT Outflows: Bitcoin US Session Roundup, Nov. 15

Nov 16, 2026•10 MIN READ

Quick Categories

Bitcoin News
Alt Coin News
Mining
Blockchain Event
Millionaire

Partnerships

Advertise With Us

Reach active Bitcoin readers, builders, and spenders.

Learn More
Megaphone
CoinMarketCapCoinMarketCap
Substack
Email

Company

  • About Us
  • Authors
  • Masthead
  • Team Verification
  • Contact Us

Resources

  • RSS Feeds
  • Editorial Policy
  • Corrections Policy
  • Terms of Service
  • Privacy Policy
  • Disclaimer
  • Sitemap

Tools

Quick access to the site tools and map-driven utility pages.

BTC Merchant MapToolMerchants by CountryToolTop Merchant CountriesToolGovernment Holdings MapTool

Coverage

RSS Feeds

Follow the core desks readers use most across Bitcoin, altcoins, mining, events, and sponsored coverage.

Bitcoin NewsDeskAlt Coin NewsDeskMiningDeskBlockchain EventDeskMillionaireDeskCrypto NewsDesk

© 2026 BitcoinInfoNews.com. All rights reserved.

Independent Bitcoin and crypto coverage with public trust, policy, and newsroom pages available sitewide.

Crypto News
News
Reviews
Analysis